The EPS beat and positive SOL-1 data provide near-term bullish momentum, but the revenue miss and widening losses are concerning. Watch for AXPAXLI NDA submission updates and SOL-R data in Q1 2027; the June Investor Day could be a catalyst for regulatory clarity.
Price Chart
Executive Summary
Ocular Therapeutix reported Q1 2026 EPS of -$0.29, beating consensus of -$0.32 by 9.4%, while revenue of $10.8M was below the $12.7M estimate. The beat was driven by lower-than-expected operating expenses, but the net loss widened to -$88.6M from -$64.1M YoY due to increased R&D spending on AXPAXLI trials. The stock will move on the EPS beat and positive SOL-1 data momentum, offset by revenue miss and cash burn concerns.
Key Financial Metrics
Key Facts
- EPS of -$0.29 beat consensus of -$0.32 by 9.4%
- Revenue of $10.8M missed consensus of $12.7M by 15%
- Net loss widened to -$88.6M from -$64.1M YoY
- Cash balance $666.7M, expected runway into 2028
- AXPAXLI NDA submission for wet AMD on track, subject to FDA discussions
- SOL-R Phase 3 topline data expected Q1 2027
- Investor Day scheduled for June 17, 2026
Financial Impact
EPS beat of $0.03 vs consensus, revenue miss of $1.9M, net loss increase of $24.5M YoY
Risk Factors
- Revenue miss of 15% vs consensus signals DEXTENZA growth stagnation
- R&D spend increased 54% YoY, pressuring cash runway despite $666.7M balance
- AXPAXLI NDA submission and FDA review timeline remain uncertain
- SOL-R non-inferiority trial may not replicate SOL-1 superiority results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287510 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | Insider Cluster | $10.90 $7.67 | ▼ −29.63% | ▼ −29.30% | $6.96 (−36.15%) |
Aug 26, 2026 5w ago | Insider Cluster | $10.82 $9.82 | ▼ −9.24% | ▼ −8.73% | $6.96 (−35.67%) |
Aug 3, 2026 8w ago | 8-K | $8.40 $10.49 | ▲ +24.88% | ▲ +23.64% | $6.96 (−17.14%) |
Jun 17, 2026 15w ago | Press Release | $9.64 $9.17 | ▼ −4.93% | ▼ −6.24% | $6.96 (−27.80%) |
Jun 12, 2026 16w ago | 8-K | $8.99 $9.88 | ▲ +9.90% | ▲ +10.65% | $6.96 (−22.58%) |
Jun 4, 2026 17w ago | Press Release | $8.80 $9.64 | ▲ +9.55% | ▲ +10.92% | $6.96 (−20.91%) |
May 28, 2026 18w ago | Insider Cluster | $9.01 $9.90 | ▲ +9.88% | ▲ +11.67% | $6.96 (−22.75%) |
May 5, 2026 21w ago | 8-K | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
May 5, 2026 21w ago | Press Release | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
Apr 30, 2026 22w ago | DEFA14A | $9.43 $8.93 | ▼ −5.30% | ▼ −10.57% | $6.96 (−26.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access